The analysis of the samples shows that alterations in 70% of the samples are significantly associated with both the presence of the disease and progression-free status, suggesting a meaningful relationship between these alterations and disease outcomes.The in silico analysis of TP53 mutations in HNSCC reveals significant alterations in TP53 and miRNA expression, and hsa-miR-133b shows promise as a novel biomarker for monitoring HNSCC. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.